Static tool
Trial-to-condition map
Matrix view mapping each registered clinical trial to the conditions it addresses. Each cell shows the trial's evidence grade where an explicit cross-link exists in the trial registry. Blank cells indicate no explicit cross-link, not a proof of absence.
| Trial | Molecule / Phase | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide Phase 3 | — | Ph 3 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| SURMOUNT-2 | Tirzepatide Phase 3 | Ph 3 | Ph 3 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| SURMOUNT-3 | Tirzepatide Phase 3 | — | Ph 3 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| SURMOUNT-4 | Tirzepatide Phase 3 | — | — | — | — | — | — | — | — | — | — | — | — | Ph 3 | Ph 3 | — |
| SURMOUNT-5 | Tirzepatide Phase 3 | — | Ph 3 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| SURPASS-2 | Tirzepatide Phase 3 | Ph 3 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| SURPASS-CVOT | Tirzepatide Phase 3 CVOT | Outcome | — | — | — | — | — | — | Outcome | — | — | — | — | — | — | — |
| SELECT | Semaglutide 2.4 mg Outcome trial | — | Outcome | — | — | — | — | — | Outcome | — | — | — | — | — | — | — |
| STEP 1 | Semaglutide 2.4 mg Phase 3 | — | Ph 3 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| STEP 2 | Semaglutide 2.4 mg Phase 3 | Ph 3 | Ph 3 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| STEP 5 | Semaglutide 2.4 mg Phase 3 | — | Ph 3 | — | — | — | — | — | — | — | — | — | — | Ph 3 | — | — |
| LEADER | Liraglutide Outcome trial | Outcome | — | — | — | — | — | — | Outcome | — | — | — | — | — | — | — |
| SUSTAIN-6 | Semaglutide Outcome trial | Outcome | — | — | — | — | — | — | Outcome | — | — | — | — | — | — | — |
| PIONEER 6 | Semaglutide (oral) Outcome trial | Outcome | — | — | — | — | — | — | Outcome | — | — | — | — | — | — | — |
| REWIND | Dulaglutide Outcome trial | Outcome | — | — | — | — | — | — | Outcome | Outcome | — | — | — | — | — | — |
| SCALE Obesity and Prediabetes | Liraglutide 3.0 mg Phase 3 | — | Ph 3 | Ph 3 | — | — | — | — | — | — | — | — | — | — | — | — |
| TRIUMPH programme | Retatrutide Phase 3 | Ph 3 | Ph 3 | — | — | Ph 3 | — | — | — | — | — | — | — | — | — | — |
| FLOW | Semaglutide 1.0 mg Outcome trial | Outcome | — | — | — | — | — | — | — | Outcome | — | — | — | — | — | — |
| SUMMIT | Tirzepatide Phase 3 | — | Outcome | — | — | — | — | Outcome | — | — | — | — | — | — | — | — |
| SYNERGY-NASH | Tirzepatide Phase 3 | Ph 3 | — | — | — | Ph 3 | — | — | — | — | — | — | — | — | — | — |
Evidence-grade legend
PreclinicalEvidence: Preclinical
Ph 1Evidence: Phase 1
Ph 2Evidence: Phase 2
Ph 3Evidence: Phase 3
OutcomeEvidence: Outcome trial evidence
LicensedEvidence: Licensed medicine evidence
Abbreviated cell labels expand to full evidence-grade badges in the legend above. Cell abbreviations: Ph 1 = Phase 1, Ph 2 = Phase 2, Ph 3 = Phase 3, Outcome = Outcome trial evidence, Licensed = Licensed medicine evidence. A dash (—) means no explicit cross-link in our trial registry.
What this map does not prove
- Cells indicate where evidence has been reported, not endorsement of that trial's findings or suitability for any individual.
- A single trial result does not generalise outside its studied population.
- Blank cells mean no explicit cross-link in our trial registry, not a proof of absence of evidence elsewhere.
- Evidence grade is the trial's overall stage, not a quality rating or measure of effect size.
Last reviewed 21 May 2026 · trial-to-condition map · Metabolic Peptides editorial team